新型评分系统预测胰腺腺癌术后生存及辅助化疗获益
多中心研究纳入1223例切缘阴性胰腺腺癌切除患者,评估第8版AJCC分期并加入术后CA19-9和肿瘤分级构建评分系统。新评分系统预测总生存的C-index为0.73(训练队列)和0.71(验证队列),优于AJCC分期,且评分中位及以上患者从辅助化疗中获益。
要点
- 第8版AJCC分期对可切除胰腺腺癌的生存区分度有限,IIA与IIB期生存无差异。
- 术后CA19-9水平和肿瘤分级可整合入AJCC分期构建评分系统。
- 新评分系统预测总生存的准确性优于AJCC分期,并可识别辅助化疗获益人群。
核心结论
- 术后CA19-9水平和肿瘤分级可整合入标准AJCC分期系统,改善风险分层并预测可切除胰腺腺癌患者的总生存和辅助化疗获益。
研究设计与样本
- 多中心研究纳入1223例接受切缘阴性胰腺切除术的胰腺腺癌患者。
- 基于AJCC病理参数和生物学标志物构建评分系统,采用Cox比例风险模型定义。
- 采用C-index和AIC评估预后准确性。
主要发现
- 第8版AJCC分期的C-index为0.62(训练队列)和0.60(验证队列),第7版为0.59(训练队列)和0.58(验证队列)。
- 第8版AJCC分期中IIA期与IIB期切除患者的生存无法区分。
- 整合术后CA19-9和肿瘤分级的新评分系统C-index为0.73(训练队列)和0.71(验证队列),AIC为4301.05(训练队列)和3309.23(验证队列)。
- 评分中位及以上的患者从辅助化疗中获得总生存获益。
临床怎么用
- 对于接受切缘阴性胰腺切除术的胰腺腺癌患者,可考虑结合术后CA19-9水平和肿瘤分级进行更精细的风险分层。
- 评分中位及以上的患者可能从辅助化疗中获益,可据此辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the application of the latest 8th American Joint Committee on Cancer (AJCC) staging system in Chinese patients and determined whether the addition of biologic markers could improve the prediction of postsurgical survival in pancreatic adenocarcinoma (PC). METHODS: This multicenter study involved 1,223 consecutive patients who underwent margin-negative pancreatectomy for PC. A scoring system was devised based on AJCC pathologic parameters and biologic markers and defined using a Cox proportional hazards model. Prognostic accuracies were evaluated by concordance index (C-index) and Akaike information criterion (AIC). RESULTS: The 8th edition AJCC staging system had a better survival distribution of PC with different stages and a similar C-index (0.62 in the training cohort, 0.60 in the validation cohort) than the 7th edition (0.59 in the training cohort, 0.58 in the validation cohort). Nevertheless, survival of resected patients with stage IIA or IIB disease was indistinguishable. Incorporation of postoperative carbohydrate antigen 19-9 (CA19-9) levels and tumor grade into the 8th edition AJCC staging system generated a scoring system with better predictive accuracy for overall survival (OS) (C-index of 0.73 and AIC of 4301.05 in the training cohort, C-index of 0.71 and AIC of 3309.23 in the validation cohort). More importantly, patients with median or higher scores experienced OS benefits from adjuvant chemotherapy. CONCLUSION: Postoperative CA19-9 levels and tumor grade are two well-known PC biologic markers that could be incorporated into a standard AJCC staging system to refine risk stratification and predict OS benefit from adjuvant chemotherapy in resected PC.
引用
- Liu L, Xu HX, He M, et al. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. Surgery. 2018. PMID: 29548773. doi:10.1016/j.surg.2018.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。